BARDINA, VALENTINA
BARDINA, VALENTINA
SCIENZE CLINICHE E BIOLOGICHE
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients.
2011-01-01 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity
2017-01-01 Alchera, E;Rolla, S; Imarisio, C; Bardina, V; Valente, G; Novelli, F; Carini, R
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
2016-01-01 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study
2018-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation
2017-01-01 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization.
2011-01-01 Simona Rolla ; Marinella Clerico; Valentina Bardina; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis.
2018-01-01 Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella.
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy
2018-01-01 Andrea Iannello, Alessandro Maglione, Giulio Ferrero, Simona Rolla, Valentina Bardina, Francesca Cordero, Michele De Bortoli, Marinella Clerico, Santina Cutrupi
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study
2017-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Ferraro, M; Cianflone, A; Lanzillo, R; Durelli, L; Cocolin, LS; Clerico, M
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome
2018-01-01 Rolla, S; Ferrocino, I; Bardina, V; Ferraro, M; Cianflone, A; Lanzillo, R; De Mercanti, S; Cocolin, L; Clerico, M
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study
2014-01-01 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study
2017-01-01 Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain
2010-01-01 Simona Rolla; Laura Conti; Raffaele De Palma; Daniela Boselli; Valentina Bardina; Gabriella Rodolico; Olli Silveinnonen; Marinella Clerico; Luca Durelli; Francesco Novelli
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
2017-01-01 Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladic, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function
2015-01-01 De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Vacca, A; Cocco, E; Vladic, A; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Edan, G; Durelli, L; Clerico, M
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
2022-01-01 Rolla S.; De Mercanti S.F.; Bardina V.; Maglione A.; Taverna D.; Novelli F.; Cocco E.; Vladic A.; Habek M.; Adamec I.; Annovazzi P.O.L.; Horakova D.; Clerico M.
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
2017-01-01 Clerico M.; Artusi C.A.; Di Liberto A.; Rolla S.; Bardina V.; Barbero P.; De Mercanti S.F.; Durelli L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. | 2011 | Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity | 2017 | Alchera, E;Rolla, S; Imarisio, C; Bardina, V; Valente, G; Novelli, F; Carini, R | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months | 2016 | De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study | 2018 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M | |
| Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation | 2017 | Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S. | |
| Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. | 2011 | Simona Rolla ; Marinella Clerico; Valentina Bardina; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. | 2018 | Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella. | |
| Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy | 2018 | Andrea Iannello, Alessandro Maglione, Giulio Ferrero, Simona Rolla, Valentina Bardina, Francesca Cordero, Michele De Bortoli, Marinella Clerico, Santina Cutrupi | |
| Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study | 2017 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Ferraro, M; Cianflone, A; Lanzillo, R; Durelli, L; Cocolin, LS; Clerico, M | |
| Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome | 2018 | Rolla, S; Ferrocino, I; Bardina, V; Ferraro, M; Cianflone, A; Lanzillo, R; De Mercanti, S; Cocolin, L; Clerico, M | |
| How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study | 2014 | S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli | |
| How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study | 2017 | Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP | |
| In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain | 2010 | Simona Rolla; Laura Conti; Raffaele De Palma; Daniela Boselli; Valentina Bardina; Gabriella Rodolico; Olli Silveinnonen; Marinella Clerico; Luca Durelli; Francesco Novelli | |
| Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses | 2017 | Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladic, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| Long Term immunological alemtuzumab effect: increase in Tregsuppressor function | 2015 | De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Vacca, A; Cocco, E; Vladic, A; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Edan, G; Durelli, L; Clerico, M | |
| Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up | 2022 | Rolla S.; De Mercanti S.F.; Bardina V.; Maglione A.; Taverna D.; Novelli F.; Cocco E.; Vladic A.; Habek M.; Adamec I.; Annovazzi P.O.L.; Horakova D.; Clerico M. | |
| Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis | 2017 | Clerico M.; Artusi C.A.; Di Liberto A.; Rolla S.; Bardina V.; Barbero P.; De Mercanti S.F.; Durelli L. |